for subcutaneous use Initial U.S. Approval: 2022
AMVUTTRA is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin‑mediated amyloidosis (hATTR amyloidosis). AMVUTTRA is used in adults only.
Facts about vutrisiran injection
Approval Date: 6/13/2022
Proprietary Name: Amvuttra
Active Ingredient(s): vutrisiran
FDA-approved use: To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage Form: Injection: 25 mg/0.5 mL in a single-dose prefilled syringe
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “vutrisiran injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For vutrisiran injection
Approved accessible "vutrisiran injection"
Amvuttra (vutrisiran) injection to treat polyneuropathy (damage of multiple nerves throughout the body) in adults with hereditary transthyretin-mediated amyloidosis, a disease that leads to organ and tissue dysfunction.
Vutrisiran, sold under the brand name Amvuttra, is a medication used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is a small interfering RNA (siRNA) that interferes with the expression of the transthyretin (TTR) gene. vutrisiran is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Note: (see Drugs@FDA for complete indication) Vutrisiran was approved for medical use in the United States in June 2022, and in the European Union in September 2022.
How can 1 go about obtaining vutrisiran injection?
If vutrisiran injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
Amvuttra (vutrisiran) injection for subcutaneous use Initial U.S. Approval: 2022
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398